Available to mentor
Dr. Heth joined the faculty at the University of Michigan Department of Neurosurgery in 2003. He was born in Iowa and primarily grew up in Iowa City. He attended the Johns Hopkins University and graduated with an undergraduate degree in Biomedical Engineering. He went to the University of Iowa for medical school and then residency. After spending a year in fellowship training with Osama Al-Mefty, MD, a pioneer in the field of skull base neurosurgery, Dr. Heth joined the faculty in 2003. He specializes in brain tumor surgery with particular interests in brain metastasis from systemic cancers, the effects of radiation treatment on the brain and brain metastasis, meningiomas, and skull base tumors. He has developed a strong interest in education and is very involved in medical student education, some specialized undergraduate programs, and residency training.
-
FellowshipUniversity of Arkansas for Medical Sciences, Neurosurgery, 2003
Brain metastasis and radiation necrosis/treatment effects on the CNS
Educational initiatives in medical students and undergraduate students, particularly "first in family" students
-
Bowden SG, Tan H, Rothbaum MG, Cook SH, Hanft S, Heth J, Morgenstern PF, Mullin JP, Orina JN, Wilson JL, Winer JL, Wolfe SQ, Chambless LB, Selden NR. J Neurosurg, 2023 Dec 1; 139 (6): 1748 - 1756.Journal ArticleMilestones for neurosurgery sub-interns: a novel evaluation tool to quantitatively differentiate residency applicants.
DOI:10.3171/2023.3.JNS23259 PMID: 37148230 -
Wadden J, John V, Niculcea M, Kong S, Aittaleb R, Cartaxo R, Verbal K, Bruzek A, Magge S, Yadavilli S, Erez N, Furth N, Shema E, Marapudi N, Heth J, Al-holou W, Garton H, Nazarian J, Koschmann C. Neuro-Oncology, 2023 Nov 10; 25 (Supplement_5): v17 - v18.Journal ArticleBIOM-58. ZERO-WASTE MOLECULAR DIAGNOSTICS FROM BIOPSY NEEDLE WASHES
DOI:10.1093/neuonc/noad179.0069 -
Umemura Y, Al-Holou W, Elaimy A, Scott AJ, Leung D, Clarke N, Kim MM, Ferris S, Thomas J, Heth J, Schipper M, Suresh K, Lawrence T, Wahl D. Neuro-Oncology, 2023 Nov 10; 25 (Supplement_5): v90 - v90.Proceeding / Abstract / PosterCTNI-61. MYCOPHENOLATE MOFETIL INHIBITS GLIOBLASTOMA PURINE METABOLISM IN HUMANS: AN INTERIM RESULT OF PHASE 0/1 CLINICAL TRIAL TO OVERCOME TREATMENT RESISTANCE IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
DOI:10.1093/neuonc/noad179.0343 -
Scott AJ, Correa LO, Edwards DM, Sun Y, Ravikumar V, Andren AC, Zhang L, Srinivasan S, Jairath N, Verbal K, Muraszko K, Sagher O, Carty SA, Hervey-Jumper S, Orringer D, Kim MM, Junck L, Umemura Y, Leung D, Venneti S, Camelo-Piragua S, Lawrence TS, Ippolito JE, Al-Holou WN, Chinnaiyan P, Heth J, Rao A, Lyssiotis CA, Wahl DR. Antioxid Redox Signal, 2023 Nov; 39 (13-15): 942 - 956.Journal ArticleMetabolomic Profiles of Human Glioma Inform Patient Survival.
DOI:10.1089/ars.2022.0085 PMID: 36852494 -
Elaimy AL, Al-Holou W, Scott A, Marini BL, Pai A, Wen B, Wang L, Sun D, Heth JA, Umemura Y, Wahl DR. International Journal of Radiation Oncology • Biology • Physics, 2023 Oct; 117 (2): e102Proceeding / Abstract / PosterA Phase 0 Study Assessing the Intracranial Activity of a Metabolic Radiosensitizer in Patients with Glioblastoma
DOI:10.1016/j.ijrobp.2023.06.872 -
Edwards DM, Hopkins A, Scott A, Mannan R, Cao X, Zhang L, Andren A, Heth JA, Muraszko K, Sagher O, Orringer D, Hollon T, Hervey-Jumper S, Venneti S, Camelo-Piragua S, Al-Holou W, Chinnaiyan A, Lyssiotis CA, Wahl DR. International Journal of Radiation Oncology • Biology • Physics, 2023 Oct; 117 (2): e101Proceeding / Abstract / PosterIdentification of Excellent Prognosis IDH Wildtype Glioblastomas Using Genomic and Metabolic Profiling
DOI:10.1016/j.ijrobp.2023.06.870 -
Umemura Y, Orringer D, Junck L, Varela ML, West MEJ, Faisal SM, Comba A, Heth J, Sagher O, Leung D, Mammoser A, Hervey-Jumper S, Zamler D, Yadav VN, Dunn P, Al-Holou W, Hollon T, Kim MM, Wahl DR, Camelo-Piragua S, Lieberman AP, Venneti S, McKeever P, Lawrence T, Kurokawa R, Sagher K, Altshuler D, Zhao L, Muraszko K, Castro MG, Lowenstein PR. Lancet Oncol, 2023 Sep; 24 (9): 1042 - 1052.Journal ArticleCombined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial.
DOI:10.1016/S1470-2045(23)00347-9 PMID: 37657463 -
Morikawa A, Serhan H, Udager AM, Bao L, Qin Z, Cheng X, Heth J, Soellner M, Merajver S, Merrill N. JCO Global Oncology, 2023 Aug; 9 (Supplement_1): 11 - 11.Proceeding / Abstract / PosterPersonalized medicine for brain metastases (BrMets) through patient-derived organoid (PDO) drug testing.
DOI:10.1200/go.2023.9.supplement_1.11